IL-17A is a proinflammatory cytokine that has received attention for its role in the pathogenesis of several autoimmune diseases. IL-17A has also been implicated in cardiac and renal allograft rejection. Accordingly, we hypothesized that depletion of IL-17A would enhance corneal allograft survival. Instead, our results demonstrate that blocking IL-17A in a mouse model of keratoplasty accelerated the tempo and increased the incidence of allograft rejection from 50 to 90%. We describe a novel mechanism by which CD4 + CD25 + regulatory T cells (Tregs) respond to IL-17A and enhance corneal allograft survival. Our findings suggest the following: 1) IL-17A is necessary for ocular immune privilege; 2) IL-17A is not required for the induction of anterior chamber-associated immune deviation; 3) Tregs require IL-17A to mediate a contact-dependent suppression; 4) corneal allograft Tregs suppress the efferent arm of the immune response and are Ag specific; 5) Tregs are not required for corneal allograft survival beyond day 30; and 6) corneal allograft-induced Treg-mediated suppression is transient. Our findings identify IL-17A as a cytokine essential for the maintenance of corneal immune privilege and establish a new paradigm whereby interplay between IL-17A and CD4 + CD25 + Tregs is necessary for survival of corneal allografts. The Journal of Immunology, 2011, 186: 6737-6745.
T he human cornea, specifically the endothelial cell layer, has little to no regenerative potential. Accordingly, this tissue is endowed with multiple anatomical, physiological, and immunoregulatory features that deviate local immune responses from a destructive pathway to one of tolerance (1, 2) . Keratoplasty has been performed on humans for over a century, and in the United States alone, .40,000 corneal transplants are performed every year (http://www.nei.nih.gov/health/cornealdisease). Ninety percent of first-time patients receiving corneal allografts that are not major and minor histocompatibility Ag matched accept their corneal transplants (3) .
The myriad of immunoregulatory components that conspire to maintain the immune privilege of the cornea fall into three categories: 1) soluble immunosuppressive molecules within the aqueous humor; 2) immunosuppressive membrane molecules expressed by corneal cells; and 3) a form of immune tolerance called anterior chamber-associated immune deviation (ACAID), which is induced when Ags enter the anterior chamber (AC). Induction of CD4 + CD25 + regulatory T cells (Tregs), which are defined by their expression of the Foxp3 transcription factor, plays a critical role in establishing tolerance when Ags are introduced into the AC or when orthotopic corneal allografts are transplanted to the eye (4) (5) (6) . Moreover, Tregs induced by AC injection of alloantigens or by penetrating keratoplasty suppress the efferent phase of delayed-type hypersensitivity (DTH) responses and can adoptively transfer corneal allograft tolerance to naive hosts who receive a subsequent corneal allograft, respectively (7, 8) . Several soluble and membrane-bound molecules have been associated with the CD4 + CD25 + Tregs. Soluble suppressive molecules such as IL-10 and active TGF-b1 are necessary for the induction of ACAID and the establishment of corneal allograft tolerance (9) . Membrane-bound suppressive mediators include CTLA-4, glucocorticoid-induced TNFR family-related receptor (GITR) gene, and cell surface-tethered TGF-b1 (5, 6) . Despite these findings, the molecular mechanisms and kinetics of CD4 + CD25 + Tregmediated suppression and their role in supporting a tolerogenic cytokine environment in corneal transplantation are still not well understood.
IL-17A, the signature cytokine of the Th17 T cell subset, was initially described as an important mediator for neutrophil induction and maturation during inflammatory responses (10) . Recently, Th17 cells and IL-17A have garnered much attention because of their involvement in autoimmune diseases that were initially attributed to Th1 cell responses (11) (12) (13) . Although some accounts describe a regulatory role for IL-17A (14-16), most reports establish a close association between IL-17A and the pathogenesis of various autoimmune diseases, including the ocular inflammatory disease uveitis (17) . However, this cytokine does not appear to be necessary for corneal allograft rejection, because IL-17 2/2 mice and wild-type mice treated with anti-IL-17A mAb do not exhibit increased survival of corneal allografts (18) (19) (20) . In fact, we found that neutralization of IL-17A abolished the immune privilege of corneal allografts and exacerbated immune rejection (19 Orthotopic corneal allograft and clinical evaluation of grafted corneas BALB/c mice were given orthotopic corneal grafts from C57BL/6 donors on the right eye and were scored twice a week for opacity, neovascularization, and edema as described previously (19) . Briefly, the degree of opacification ranged from 0 to 4+, with 0 = clear; 1+ = minimal superficial opacity; 2+ = mild deep stromal opacity with pupil margin and iris visible; 3+ = moderate stromal opacity with pupil margin visible but iris structure obscured; and 4+ = complete opacity, with pupil and iris totally obscured. Corneal grafts were considered rejected upon two successive scores of 3+.
Cytokine depletion protocol
The anti-IL-17A mAb hybridoma was generated by the University of Texas Southwestern Hybridoma Facility as described previously (19) . Anti-CD25 hybridoma (catalog number TIB-222; PC615.3) was purchased from American Type Culture Collection (Manassas, VA). mAbs were isolated from hybridoma cultures and affinity purified. Rat IgG used for isotype Ab controls was purchased from Sigma-Aldrich (St. Louis, MO). BALB/c mice were injected i.p. with 500 mg Ab on days 24 to 22 prior to corneal transplantation, and biweekly injections of Ab were continued thereafter to day +60.
AC injections
Injection of alloantigenic cells into the AC of the mouse eye has been described previously (21) . Briefly, a Hamilton automatic dispensing apparatus was used to inject 1 3 10 5 nonadherent C57BL/6 splenocytes (5 ml) into the AC of anesthetized BALB/c mice.
Delayed-type hypersensitivity
An ear-swelling assay was used to measure DTH responses as described previously (19) . Briefly, BALB/c mice were immunized s.c. with C57BL/6 spleen cells. Seven days later, C57BL/6 splenocytes were injected into the ear pinnae, and ear swelling was measured 24 h later using an engineers' micrometer. Results were calculated by using the formula: specific ear swelling = (24-h measurement 2 0-h measurement) experimental ear 2 (24-h measurement 2 0-h measurement) negative control ear.
Abs and flow cytometry
For in vitro blocking assays, monoclonal anti-mouse CTLA-4, anti-mouse GITR, anti-pan TGF-b (1-3), rat IgG 2A isotype control, and mouse IgG 1 isotype control were purchased from R&D Systems (Minneapolis, MN). The Abs used for flow cytometric analyses included PerCPCy5.5-conjugated rat anti-mouse CD4 (eBioscience, San Diego, CA), allophycocyanin-conjugated rat anti-mouse CD25 (BD Biosciences, San Jose, CA), allophycocyanin-conjugated Armenian hamster anti-mouse CTLA-4 (eBioscience), allophycocyanin-conjugated rat anti-mouse GITR (eBioscience), allophycocyanin-conjugated rat anti-mouse Foxp3 (eBioscience), allophycocyanin-conjugated streptavidin (eBioscience), and biotinylated anti-TGF-b1 Ab (R&D Systems). All flow cytometric analyses were performed on a FACSCalibur with CellQuest software (BD Biosciences).
CFSE suppression assay
Suppression assays were set up as described previously (7 cells/well in 2 ml complete RPMI 1640 medium supplemented with 1 mg/ ml anti-CD3ε Ab for 72 h at 37˚C. ELISAs for IL-17A, IFN-g, and TNF-a were performed on culture supernatants, according to the manufacturer's instructions (R&D Systems).
Quantitative real-time PCR
Total RNA was isolated from FACS-sorted CFSE 2 CD4 + CD25 + Tregs from corneal allograft acceptor mice using the Maxwell 16 Cell LEV Total RNA Purification kit (Promega, Madison, WI) following 72 h of incubation with CFSE-labeled naive CD4 + T cells. Real-time PCR was performed using the RT 2 First-Strand and RT 2 SYBR Green kits with preformulated primers for Foxp3 (PPM05497F), CTLA-4 (PPM03217E), GITR (PPM03742E), TGF-b1 (PPM02991A), and GAPDH (PPM05497F) (SA Biosciences, Frederick, MD). The results were analyzed by the comparative threshold cycle method and normalized with GAPDH as an internal control.
Preparation of APCs
Splenic lysates were generated from C57BL/6 or C3H mice as described previously (19) . Naive BALB/c APCs were isolated by incubating 10 ml BALB/c splenocytes equally divided onto two 100-mm Primaria plates (BD Falcon, Franklin Lakes, NJ) at 37˚C for 1 h, and nonadherent cells were removed by vigorous washing. The remaining adherent APCs were cultured in 4 ml complete RPMI 1640 medium supplemented with 10% FBS and pulsed with the C57BL/6 cell lysate or C3H cell lysate (1 ml). Cell cultures were incubated at 37˚C overnight and washed with HBSS.
Local adoptive transfer assay
The local adoptive transfer (LAT) assay to test the efferent suppression and Ag specificity of CD4 + CD25 + Tregs has been described previously (22) . Briefly, Tregs were incubated with BALB/c APCs pulsed with either C57BL/6 or C3H splenic lysates and CD4 + T effector cells from corneal allograft rejectors in a 1:1:1 ratio. The right ear pinnae of naive BALB/c mice were injected with 20 ml (1 3 10 6 cells) of the mixed-cell population. The opposite ear was injected with HBSS as a negative control. Ear swelling was measured 24 h later to assess DTH.
Statistical analysis
The log-rank test was used for statistical analysis of the differences in the tempo of corneal graft rejection from the Kaplan-Meier survival curves (7) . Statistical significance for other experiments was calculated by the twotailed t test. Comparisons yielding p , 0.05 were considered significantly different.
Results

IL-17A is required for corneal allograft survival
Previous studies have indicated that allograft rejection occurs in IFN-g-deficient hosts (19) . On the basis of this observation and reports that IL-17A exacerbates allograft rejection (23, 24) , we hypothesized that IL-17A depletion would promote corneal allograft survival. BALB/c mice were treated systemically with either monoclonal anti-IL-17A Ab or an IgG isotype control Ab twice per week before and after the application of orthotopic C57BL/6 corneal allografts. The isotype control-treated group rejected 50% of their C57BL/6 corneal allografts with a mean rejection time (MRT) of 35.2 6 8.0 d and a median survival time (MST) of 52 d (Fig. 1) . Interestingly, treatment with anti-IL-17A Ab resulted in a 90% incidence of rejection and an MRT of 22.4 6 8.1 d and an MST of 24 d (Fig. 1) . The rates of corneal allograft rejection between the rat IgG isotype control and anti-IL-17A-treated groups were statistically different (p , 0.05). These data show that instead of extending corneal allograft survival, depletion of IL-17A in mice exacerbated corneal allograft rejection.
Depletion of IL-17A does not enhance Th1 immune responses responsible for corneal allograft rejection and does not affect the induction of ACAID Corneal allograft rejection is associated with the acquisition of Th1-mediated donor-specific DTH responses, whereas the absence of DTH responses to donor alloantigens correlates with corneal allograft survival (25) (26) (27) (28) (29) . Accordingly, we investigated whether anti-IL-17A Ab treatment enhanced DTH responses against alloantigens presented by corneal allografts (9) . BALB/c mice were treated with 500 mg anti-IL-17A on days 24 and 22, prior to s.c. immunization with C57BL/6 unfractionated splenocytes on day 0, and twice per week following s.c. immunization. DTH was assessed by injecting C57BL/6 splenocytes into the ear pinnae on day +14 postimmunization and by measuring ear swelling 24 h later. No significant differences in the ear swelling were detected between the anti-IL-17A-treated group and the rat IgG-treated group ( Fig. 2A) . These results show that DTH responses in mice depleted of IL-17A were not enhanced and suggest that elevated Th1 responses were not responsible for the increased incidence and swifter tempo of corneal allograft rejection in anti-IL-17A-treated hosts.
Corneal allograft survival is intimately associated with the development of ACAID, a unique form of immune tolerance that is elicited by the introduction of foreign Ags into the AC of the eye (30) . Conditions that abrogate ACAID and terminate immune privilege invariably culminate in corneal allograft rejection (30) . To test whether IL-17A is required for the induction of ACAID, BALB/c mice were treated with the anti-IL-17A mAb or isotype control Ab as described above and given an AC injection of C57BL/6 nonadherent spleen cells on day 0. Seven days later, ACinjected mice and control mice were immunized s.c. with C57BL/6 spleen cells. To assess DTH, C57BL/6 splenocytes were injected into the ear pinnae 7 d after s.c. immunization, and ear swelling was measured 24 h later. Mice treated with isotype control Ab and injected with allogeneic spleen cells in the AC demonstrated suppressed ear swelling compared with s.c. immunized mice that served as the positive DTH control (Fig. 2B) . Similarly, mice treated with anti-IL-17A Ab and injected with allogeneic spleen cells in the AC demonstrated suppressed ear swelling. Taken together, these results indicate that depletion of IL-17A did not prevent the induction or expression of ACAID and thus rules out the abrogation of ACAID as an explanation for the increased incidence and tempo of corneal allograft rejection in anti-IL-17A-treated mice.
IL-17A is required for the generation of CD4 + CD25
+ Tregs that promote corneal allograft survival
The increased incidence of corneal allograft rejection following anti-IL-17A treatment suggested a novel role for this cytokine in maintaining ocular immune privilege in corneal transplantation. Recent data demonstrated that CD4 + CD25 + Tregs were necessary for prevention of allograft rejection in clinical settings and in animal transplantation models including murine models of corneal allograft transplantation (21, 31 ). Accordingly, experiments tested whether IL-17A was required for the function of CD4 + CD25 + Tregs that promote corneal allograft survival. BALB/c mice were treated with either anti-IL-17A or anti-CD25 Abs on days 24 and 22 prior to corneal allograft transplantation and twice per week thereafter. Mice treated with anti-IL-17A rejected 90% of their corneal allografts (Fig. 3A) . Similarly, all mice treated with anti-CD25, which disables CD4 + CD25 + Tregs, rejected their corneal allografts. The MSTs for the anti-IL-17A or anti-CD25-treated groups were 17 and 15 d, respectively, and the tempo of rejection between the Ab-treated and isotype control-treated mice was significantly different (p , 0.05).
The 17A-treated and isotype control-treated cocultures containing CD4 + CD25 + rejector Tregs and CD4 + T effector cells. To further ascertain that the loss in the suppressive potential of the acceptor CD4 + CD25 + Tregs following depletion of IL-17A was not intrinsic to our assay, a conventional thymidine proliferation assay was also used to assess suppression of naive CD4 + T effector cell proliferation (Fig. 3C) (Fig. 3E) . By contrast, IL-17A, IFN-g, and TNF-a were detected in supernatants of anti-CD3ε-stimulated CD4 + CD25 2 T cells (potential effector cells) from corneal allograft acceptor mice.
CD4 + CD25 + Treg suppression of effector CD4 + T cells is contact dependent and requires IL-17A
The mechanisms CD4 + CD25 + Tregs use to mediate their suppressive effects may include the production of soluble immunosuppressive factors and/or cell-cell contact with effector T cells. In vitro Transwell culture assays were used to determine whether corneal allograft acceptor Treg-mediated suppression was contact dependent or mediated through soluble factors. Separation of CD4 + CD25 + Tregs and CD4 + T effector cells with Transwell membranes in the cocultures resulted in an 80% reduction in Tregmediated suppression compared with cocultures without a Transwell membrane (Fig. 4A) . These results suggested that corneal acceptor CD4 + CD25 + Treg-mediated suppression was primarily dependent on membrane-bound suppressive molecules. Previous experiments described above demonstrated that IL-17A was required for CD4 + CD25 + Treg-suppressive activity (Fig. 3) resulted in a $2-fold decrease in the expression of Foxp3 and three membrane-bound suppressive molecules, namely CTLA-4, GITR, and TGF-b1 (Fig. 4B ), which coincided with reduced expression of intracellular Foxp3 expression and surface expression of CTLA-4, GITR, and membrane-bound TGF-b1 (Fig. 4C) as determined by flow cytometry. To confirm that CD4 + CD25 + Tregs mediated the inhibition of CD4 + effector T cell activation through one or more of the membrane-bound suppressive molecules, blocking Abs (anti-CTLA-4, anti-GITR-L, and anti-TGF-b1) were added to coculture assays containing CD4 + CD25 + Tregs and CD4 + T effector cells. When used independently, the Abs did not cause a significant decrease in suppression when compared with the isotype controls. By contrast, simultaneous blockade of both GITR and CTLA-4 led to a significant decrease in suppression (p , 0.05) and the most dramatic loss of suppression came with addition of all three blocking Abs, which inhibited ∼50% of the suppression mediated by CD4 + CD25 + Tregs (Fig. 4D) . Our data suggest that IL-17A plays a crucial role in CD4 + CD25 + Treg contact-mediated suppression. + CD25 + Tregs suppress the efferent phase of the alloimmune response. To assess whether the efferent suppression was Ag specific, LAT assays were performed using naive BALB/c APCs pulsed with either C3H or C57BL/6 spleen cell lysates and incubated with CD4 + T effector cells isolated from BALB/c mice that had rejected either C3H or C57BL/6 corneal allografts, respectively. CD4 + CD25 + Tregs from BALB/c mice that accepted C57BL/6 allografts were added in equal proportions to the cell mixtures and injected into the ear pinnae of naive BALB/c mice. CD4 + CD25 + Tregs from BALB/c mice that accepted C57BL/6 corneal allografts inhibited DTH responses to C57BL/6 alloantigens (p , 0.05) but had no effect on the DTH response to C3H alloantigens, demonstrating the Ag specificity of the corneal allograft-induced CD4 + CD25 + Treg-mediated suppression (Fig.  5B) . + Tregs that promote corneal allograft survival. A, BALB/c mice were treated with anti-IL-17A and anti-CD25 or isotype control Ab prior to receiving C57BL/6 corneal allografts. p , 0.05 by Kaplan-Meier survival analysis between cytokinedepleted groups and rat IgG isotype control group (n = 10 mice/group), and the results were consistent in three independent experiments. B, In vitro CFSE suppression assay was used to assess the regulatory potential of Tregs from acceptor and rejector mice in the presence of either anti-IL-17A or isotype control IgG. Suppression was based on naive CD4 + CFSE + T effector cell expression of CD25 following 72 h of coculture with CD4 + CD25 + Tregs isolated from corneal allograft acceptor mice and in the presence of anti-CD3ε Ab. *p , 0.05; n = 3 mice/group (allograft acceptors and allograft rejectors) with results being consistent in two independent experiments. C, The ability of acceptor CD4 + CD25 + Tregs, treated with either rat IgG isotype control or anti-IL-17A Ab, to suppress the proliferation of anti-CD3ε Ab-stimulated naive CD4 + T cells was assessed in vitro. Cocultures treated with anti-IL-17A experienced significantly higher proliferation and thymidine incorporation compared with the rat IgG-treated groups. *p , 0.05; n = 3 acceptor mice/group with results being consistent in two independent experiments. D, The ability of exogenous rIL-17A to suppress CD4 + T effector cell activation was determined in an in vitro CFSE suppression assay. This experiment was performed two separate times with similar results using a total of eight naive mice. *p , 0.05. E, CD4
CD4
+ CD25 + Treg suppression is not required for long-term corneal allograft survival
The ability of IL-17A-activated CD4 + CD25 + Tregs to suppress the efferent arm of the immune response suggests that hosts with long-term surviving corneal allografts possess Tregs that persist indefinitely and promote the survival of subsequent corneal allografts. To explore this possibility, BALB/c mice bearing clear C57BL/6 allografts for 30 d were treated with either a combination of anti-IL-17A and anti-CD25 Ab or an isotype control Ab twice per week for 60 d. Interestingly, combined treatment with anti-IL-17A and anti-CD25 Abs, which is known to elicit the swift rejection of corneal allografts if administered immediately prior to transplantation, did not significantly affect the survival of corneal allografts that had been clear for 30 d (Fig. 6) . These results indicate that the need for CD4 + CD25
+ Treg-mediated suppression is transient and was necessary for corneal allograft survival during the initial sensitization phase of the alloimmune response but is superfluous 30 d posttransplantation. + Tregs was assessed by an in vitro the CFSE-based immunosuppression assay. *p , 0.05; two independent experiments were performed using a total of 12 corneal allograft acceptor mice, which yielded similar results. APC, allophyocyanin; mTGF-b1, membranebound TGF-b1.
Discussion
In the past 50 y, animal studies have revealed that immune privilege of corneal allografts is maintained by three immune adaptations including 1) inhibition of alloimmune response induction, 2) induction of tolerance, and 3) the presence of soluble factors and cell membrane-bound molecules that either delete or block the function of immune effector elements at the graft/host interface (1, 2) . It has long been assumed that the survival of corneal allografts is associated with active suppression of alloimmune responses against the donor's alloantigens. Hosts with long-term surviving corneal allografts display Ag-specific suppression of donor-specific DTH responses (35) . Moreover, disabling ACAID Treg activity invariably abrogates corneal allograft immune privilege and provokes corneal allograft rejection (30 Tregs to naive recipients results in a significant enhancement of corneal allograft survival (7) . The results presented in this paper provide further evidence that CD4 + CD25 + Tregs contribute to corneal allograft survival and demonstrate that Tregs support corneal immune privilege through an IL-17A-dependent mechanism. Moreover, our results demonstrate that blockade of IL-17A in vivo with anti-IL-17A mAb increases the tempo and incidence of corneal allograft rejection, suggesting that IL-17A might be necessary for ocular immune privilege in recipients of penetrating keratoplasty. A preponderance of evidence indicates that IL-17A cross-regulates IFN-g production by Th1 cells (36) . Thus, it might be argued that depletion of IL-17A would promote increased IFNg production and enhanced activation of Th1 cells. However, we found no evidence of exaggerated Th1-mediated DTH immune responses in anti-IL-17A-treated mice. It has also been suggested that corneal allograft survival is closely associated with the corneal allograft's capacity to induce ACAID (21) . Accordingly, IL-17A may play a role in the induction of ACAID and promote corneal allograft survival by this mechanism. However, our results indicate that anti-IL-17A treatment does not affect the generation of ACAID, and thus, this possibility is an unlikely explanation for the loss of corneal allograft immune privilege in anti-IL-17A-treated hosts. Instead, the weight of evidence suggests that IL-17A is necessary for the function of corneal allograft-induced CD4 + CD25 + Tregs at the early sensitization phase and is not required for long-term graft survival.
Although IL-17A is recognized for its proinflammatory properties, our findings indicate a novel function for this cytokine, suggesting that it is required by CD4 + CD25 + Tregs to sustain an immunosuppressive response and thereby ensure corneal allograft survival. It has been reported that human CD4 + CD25 + Tregs are + Tregs from BALB/c hosts were mixed with CD4 + T cells from either BALB/c mice that rejected C57BL/6 corneal allografts or BALB/c mice that rejected a C3H corneal allograft. APCs pulsed with either C57BL/6 or C3H alloantigens were admixed with the aforementioned T cell suspensions and injected into the ear pinnae of naive BALB/c mice. Ear swelling was measured 24 h later. *p , 0.05. This experiment was performed twice with similar results; n = 5/group. able to produce IL-17A (37 (38) , and TNF-a and IFN-g are needed for generating and potentiating CD4 + CD25 + Tregs in other models of immune regulation (32) (33) (34) . In vivo treatment with anti-IL-17A also induces CD4 + T cells to produce IL-4, which is known to render CD4 + T cells resistant to the suppressive activity of CD4 + CD25 + Tregs (19, 39) .
As mentioned previously, IL-17A itself is not the suppressive factor that directly promotes corneal allograft survival. + Tregs and CD80/CD86 expressed by dendritic cells upregulates expression of IDO (5) . IDO catabolizes tryptophan to kynurenine leading to T cell starvation and apoptosis (45) . Although mouse models have shown that genetic enhancement of IDO expression results in prolonged corneal allograft survival in high-risk hosts, the direct or indirect role IDO plays in CD4 + CD25 + Tregs suppression remains to be determined (46) . One additional important finding emerges from the current study. It appears that CD4 + CD25 + Tregs are not necessary for the continued survival of corneal allografts beyond day 30, because administration of anti-CD25 and anti-IL-17A Abs at this time point does not adversely affect long-term corneal allograft survival.
In summary, this paper presents the novel finding that the proinflammatory cytokine IL-17A is required to induce a corneal allograft-mediated Treg population that is distinctly different from the Tregs induced when Ags are injected into the AC of the eye. Our results demonstrate that corneal allograft-induced Treg activity is not required for long-term survival of corneal allografts. With this in mind, it might be possible to devise strategies to enhance corneal allograft survival in high-risk hosts by enhancing CD4 + CD25 + Treg function through IL-17A-based therapeutic modalities aimed at the initial sensitization phase.
